Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. Materials and Methods In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m2 orally on days 1, 8, and 15, and bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23. Results At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade ≥ 3 neuropathy observed. Conclusion These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327).
Abstract
Purpose A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. Materials and Methods In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m2 orally on days 1, 8, and 15, and bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23. Results At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade ≥ 3 neuropathy observed. Conclusion These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327).
참고문헌 (30)
- Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
- Attal M, "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome", N Engl J Med, 335, pp.91~97 (1996)
- Voorhees PM, "Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma : the GRIFFIN trial", Blood, 136, pp.936~945 (2020)
- Moreau P, "Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma(CASSIOPEIA) : a randomised, open-label, phase 3 study", Lancet, 394, pp.29~38 (2019)
- McCarthy PL, "Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma : a meta-analysis", J Clin Oncol, 35, pp.3279~3289 (2017)
- Roussel M, "Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma : a phase II study by the Intergroupe Francophone du Myelome", J Clin Oncol, 32, pp.2712~2717 (2014)
- Jung J, "Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea : the KMM1807 study", Int J Hematol, 112, pp.84~95 (2020)
- Rahman S, "Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma", Transpl Infect Dis, 21, pp.e13114~ (2019)
- Ladetto M, "Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma", J Clin Oncol, 28, pp.2077~2084 (2010)
- Chaudhry V, "Characteristics of bortezomib-and thalidomide-induced peripheral neuropathy", J Peripher Nerv Syst, 13, pp.275~282 (2008)
- Kim YK, "Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone(Vel-CTD)regimen in patients with relapsed or refractory multiple myeloma : a phase II study", Ann Hematol, 89, pp.475~482 (2010)
- Richardson PG, "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma", N Engl J Med, 352, pp.2487~2498 (2005)
- Morgan GJ, "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation : MRC Myeloma IX randomized trial results", Haematologica, 97, pp.442~450 (2012)
- Reeder CB, "Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma : high res-ponse rates in a phase II clinical trial", Leukemia, 23, pp.1337~1341 (2009)
- Kumar S, "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma", Lancet Oncol, 17, pp.e328~46 (2016)
- Cosman F, "Clinician’s guide to prevention and treatment of osteoporosis", Osteoporos Int, 25, pp.2359~2381 (2014)
- van de Velde HJ, "Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma", Haematologica, 92, pp.1399~1406 (2007)
- Mellqvist UH, "Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma : a Nordic Myeloma Study Group randomized phase 3 trial", Blood, 121, pp.4647~4654 (2013)
- Tacchetti P, "Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma(GIMEMA-MMY-3006) : long-term follow-up analysis of a randomised phase 3, open-label study", Lancet Haematol, 7, pp.e861~73 (2020)
- Rosinol L, "Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma", Blood, 134, pp.1337~1345 (2019)
- Cavo M, "Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone conso-lidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma(EMN02", HO95) : a multicentre, randomised, open-label, phase 3 study, 2020, pp.7, e456~68
- Stadtmauer EA, "Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma : results of the BMT CTN 0702 trial", J Clin Oncol, 37, pp.589~597 (2019)
- Zhang S, "Bortezomib-based consolidation or maintenance therapy for multiple myeloma : a meta-analysis", Blood Cancer J, 10, pp.33~ (2020)
- Mills JR, "High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma", Blood Cancer J, 7, pp.e590~ (2017)
- Mellors PW, "Time to plateau as a predictor of survival in newly diagnosed multiple myeloma", Am J Hematol, 93, pp.889~894 (2018)
- Mariette X, "Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy", Cancer, 76, pp.1559~1563 (1995)
- Sezer O, "Myeloma bone disease : recent advances in biology, diagnosis, and treatment", Oncologist, 14, pp.276~283 (2009)
- Terpos E, "The use of biochemical markers of bone remodeling in multiple myeloma : a report of the International Myeloma Working Group", Leukemia, 24, pp.1700~1712 (2010)
- Heider U, "Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment", Eur J Haematol, 77, pp.233~238 (2006)
- Tosi P, "First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma", Eur J Haematol, 76, pp.399~404 (2006)